UPCC 17419: A Phase 1b-2 Open-Label Study of JNJ-68284528 a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
Brief description of study
The main purpose of this study is to investigate the use of a new, experimental drug called JNJ-68284528 in subjects with multiple myeloma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Myeloma
-
Age: - 99 Years
-
Gender: All
Updated on
29 Jan 2020.
Study ID: 833182